Interferon beta-1b inhibits reactive oxygen species production in peripheral blood monocytes of patients with relapsing-remitting multiple sclerosis

被引:18
|
作者
Lucas, M
Sánchez-Soliño, O
Solano, F
Izquierdo, G
机构
[1] Virgen Macarena Univ Hosp, Mol Biol Serv, Seville, Spain
[2] Schering Espana SA, Madrid, Spain
[3] Virgen Macarena Univ Hosp, Neurol Serv, Seville, Spain
关键词
D O I
10.1016/S0197-0186(98)00014-X
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We studied the rate of reactive oxygen species (ROS) production by monocytes 'ex vivo' in a cohort of healthy individuals, in a group of MS patients undergoing treatment with interferon beta-lb and another group of MS patients who refused treatment with interferon beta-1b. The rate of ROS production in healthy individuals was slightly lower than in non-treated MS patients. The lower rate of ROS production was obtained in monocytes of MS patients treated with interferon beta-1b. These results indicate that the treatment of relapsing-remitting MS patients with interferon beta-lb rendered the NADPH oxidase of the monocytes less sensitive to trigger reactive oxygen species (ROS). (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:101 / 102
页数:2
相关论文
共 50 条
  • [22] Comparison of permanent black hole lesion number in relapsing-remitting multiple sclerosis with interferon beta-1b to glatiramer acetate
    Rocca, M. A.
    Camesasca, Fabiano
    Cook, Stuart
    Comi, Giancarlo
    Goodin, Douglas S.
    O'Connor, Paul W.
    Jeffrey, Douglas
    Hartung, Hans-Peter
    Arnason, Barry G. W.
    Kappos, Ludwig
    Wolinsky, Jerry
    Pohl, Christoph
    Beckmann, Karola
    Croze, Ed
    Sandbrink, Rupert
    Arnold, Douglas L.
    Cutter, Gary
    Bogumil, Timon
    Knappertz, Volker
    Filippi, Massimo
    MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (08) : 1017 - 1017
  • [23] Apoptosis of peripheral blood lymphocytes in patients with relapsing-remitting multiple sclerosis
    Petelin, Z
    Brinar, V
    Petravic, D
    Zurak, N
    Dubravcic, K
    Batinic, D
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S172 - S173
  • [24] Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing/remitting multiple sclerosis
    Deisenhammer, F
    Giovannoni, G
    MULTIPLE SCLEROSIS JOURNAL, 2004, 10 (06)
  • [25] Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis
    Zhang, Jian
    Shi, Shengliang
    Zhang, Yueling
    Luo, Jiefeng
    Xiao, Yousheng
    Meng, Lian
    Yang, Xiaobo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (11):
  • [26] Interferon beta-1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis:: results of a Markov disease model for Sweden and the UK
    Kobelt, G
    Jönsson, L
    Fredrikson, S
    JOURNAL OF NEUROLOGY, 2004, 251 : 44 - 44
  • [27] Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b
    Richert, ND
    Ostuni, JL
    Bash, CN
    Duyn, JH
    McFarland, HF
    Frank, JA
    AMERICAN JOURNAL OF NEURORADIOLOGY, 1998, 19 (09) : 1705 - 1713
  • [28] COST-UTILITY ANALYSIS OF PEGYLATED INTERFERON BETA-1A VERSUS INTERFERONS BETA-1A AND BETA-1B IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN COLOMBIA
    Ordonez, J. E.
    VALUE IN HEALTH, 2017, 20 (05) : A193 - A194
  • [29] A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b
    Ricci, A
    Cucci, A
    Rovera, A
    Clerico, M
    Durelli, L
    NEUROLOGY, 2006, 66 (05) : A236 - A236
  • [30] Azathioprine and interferon β-1b treatment in relapsing-remitting multiple sclerosis
    Milanese, C
    La Mantia, L
    Salmaggi, A
    Caputo, D
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2001, 70 (03): : 413 - 414